Complications in Process Simulation Execution

News
Article
Pharmaceutical TechnologyPharmaceutical Technology-05-15-2020
Volume 2020 eBook
Issue 2
Pages: 10–14, 43

Regulators have exaggerated expectations for simulated media fills.

Regulators have exaggerated expectations for simulated media fills.

This article reviews aspects of media fill execution in which regulatory expectations have created artificial compliance concerns and significant practical difficulties.

 

Read this article in Pharmaceutical Technology's Biologics and Sterile Drug Manufacturing eBook.

Article Details

Pharmaceutical Technology
eBook: Biologics and Sterile Drug Manufacturing
May 2020
Pages: 10–14, 43

Citation

When referring to this article, please cite it as J. Agalloco, "Complications in Process Simulation Execution," Pharmaceutical Technology Biologics and Sterile Drug Manufacturing eBook (May 2020).

Articles in this issue
PTebook0520_PreFilled-Syringes_Main-Image.gif
On Point: Biologics Drive Growth in Pre-Filled Syringes
Screen Shot_225.jpg
Instrumenting Single-Use Processes
Ebook_Contamination Control_225.jpg
Considerations in Contamination Control
Best systems and equipment for contamination control
Ebook_Development_225.jpg
Building Data Quality In Generates Quality Data Out
PTeBook0520_ContaminationCellTherapy_main225.jpg
Detecting Contamination in Cell Therapies
PTeBook0520_SeparationViralVector_main225.jpg
Optimizing Viral Vector Manufacturing for Gene Therapy
PTEebook0520_thermo.jpg
Minimizing Contamination During Biopharma R&D
PTEebook0520_agalloco-1.jpg
Complications in Process Simulation Execution
Recent Videos
Tore Bergsteiner from MAIN5 details his predictions for how the mega trends will shape the bio/pharma industry in 2025 and beyond.
Roger Viney from ICE Pharma discusses the quality and compliance issues surrounding the use of animal-derived ingredients in the bio/pharma industry.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content
Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

Benuvia Awarded NIH Contract for GMP Synthesis of Psilocybin, Other Drug Substances

Patrick Lavery
March 25th 2025
Article

The contract will support R&D of high-quality APIs for substance use disorders and mental health conditions, starting with synthesis and scale-up of psilocybin, which is derived from mushrooms.

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
June 25th 2024
Podcast

In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

FDA Approves Novartis Oral Treatment for Adults with C3 Glomerulopathy

Patrick Lavery
March 25th 2025
Article

Fabhalta (iptacopan) received a positive opinion for treatment of C3G from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) and has been approved twice before by FDA.

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Drug Solutions Podcast: All About Data: Looking at the EHDS in More Detail

Felicity Thomas
May 28th 2024
Podcast

In this episode, Alexander Natz from EUCOPE chats about the European Health Data Space.

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com

Latigo Biotherapeutics Raises $150 Million to Advance Non-Opioid Pain Therapeutics

Feliza Mirasol
March 24th 2025
Article

With financing led by Blue Owl Capital, Latigo will use the funds to further develop non-opioid pain treatments as well as develop other candidates in its pipeline.

Hand shaking which print screen on wooden cube block in front of human icon for business deal and agreement concept | Image Credit: © Dilok – © Dilok - stock.adobe.com

Shilpa Biologicals and mAbTree Biologics to Collaborate on Novel Immuno-Oncology Asset

Feliza Mirasol
March 18th 2025
Article

The partnership aims to develop and commercialize a novel checkpoint inhibitor for immuno-oncology applications.